GSK PLC
GSK
Company Profile
Business description
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Contact
79 New Oxford Street
LondonWC1A 1DG
GBRT: +44 2080475000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
68,629
Stocks News & Analysis
stocks
5 undervalued US stocks that crushed earnings
Names like Sony and GSK are still cheap despite impressive earnings beats for Q2 2024.
stocks
Magnificent Seven vs. the ‘Granolas’: How does Europe’s version stack up?
‘Granolas’ stocks are profitable, diversified, cheap—and posting big returns.
stocks
10 top global stocks based on 2023 expert forecasts
Well-respected investment firms expect non-US stocks to outperform over the next decade. Here are Morningstar’s best international-stock picks today.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,053.20 | 142.30 | -1.74% |
| CAC 40 | 7,781.34 | 134.74 | -1.70% |
| DAX 40 | 22,068.94 | 392.58 | -1.75% |
| Dow JONES (US) | 41,583.90 | 715.80 | -1.69% |
| FTSE 100 | 8,559.05 | 99.80 | -1.15% |
| HKSE | 23,119.58 | 307.02 | -1.31% |
| NASDAQ | 17,322.99 | 481.04 | -2.70% |
| Nikkei 225 | 35,617.56 | 1,502.77 | -4.05% |
| NZX 50 Index | 12,270.00 | 17.46 | -0.14% |
| S&P 500 | 5,580.94 | 112.37 | -1.97% |
| S&P/ASX 200 | 7,843.40 | 138.60 | -1.74% |
| SSE Composite Index | 3,335.75 | 15.56 | -0.46% |